Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasms 2Multiple Myeloma 2Solid Tumors 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasms, Plasma Cell 1Hematologic Diseases 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Cyclophosphamide 62Dexamethasone 60Melphalan 54Peripheral Blood Stem Cell Transplantation 49Bortezomib 40Busulfan 39fludarabine phosphate 34Filgrastim 32Lenalidomide 30Thalidomide 27Tacrolimus 25Antilymphocyte Serum 23Radiotherapy 22Mycophenolic Acid 17Methotrexate 17Prednisone 15Etoposide 15sargramostim 14Cyclosporine 14fludarabine 12Methylprednisolone 11Granulocyte Colony-Stimulating Factor 11Calcium Dobesilate 11Whole-Body Irradiation 10Doxorubicin 9Carmustine 9pomalidomide 8Vincristine 8Interferon-alpha 8Cord Blood Stem Cell Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms, Plasma Cell × LCL161 × Clear all
NCT03111992 2022-02-09

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Novartis

Phase 1 Completed
26 enrolled
Plasma cell

Hematologic Diseases, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡